Chikungunya vs. Dengue: How to Distinguish Them Accurately?
发布时间：2025.07.31
Guangdong’s Foshan city issued an announcement late last night (July 30), stating that, in accordance with the relevant emergency response plan for public health emergencies and taking into account the current situation of chikungunya prevention and control, it has decided to activate a Level III response to the public health emergency.
To strengthen prevention and control efforts against mosquito-borne infectious diseases such as chikungunya and dengue fever in Foshan, swiftly reduce adult mosquito populations, and effectively interrupt transmission routes, Foshan will launch a week-long intensive adult mosquito‑control campaign across the city starting July 31.
As acute infectious diseases transmitted by the bite of Aedes mosquitoes, what are the differences between chikungunya fever and dengue fever, and what key considerations should be kept in mind during diagnosis and prevention efforts?
Chikungunya vs. Dengue Fever
|
|
Chikungunya fever | Dengue fever |
|---|---|---|
|
Routes of transmission |
Both are transmitted by Aedes albopictus and Aedes aegypti. |
|
|
Pathogen |
Chikungunya virus has only one serotype. |
Dengue virus has four serotypes. |
|
Incubation period |
Typically 1–12 days, most commonly 3–7 days. |
Typically 1–14 days, most commonly 5–9 days. |
|
Infectious period |
Typically from the day of onset to within 7 days after onset. |
Typically from 1 day before onset to within 5 days after onset. |
|
Susceptible population |
Generally susceptible; lifelong immunity is acquired following infection. |
It is generally susceptible; following infection, lasting immunity develops against the same serotype, but effective protection against other serotypes is not conferred. |
|
Epidemiological characteristics |
It occurs primarily in the Americas, Asia, and Africa; in China, it has not yet become endemic. |
It occurs primarily in Latin America, the Western Pacific, Southeast Asia, and the Eastern Mediterranean; several provinces—including Guangdong, Yunnan, Fujian, Zhejiang, Guangxi, and Hainan—have experienced multiple outbreaks of locally transmitted dengue fever resulting from imported cases. |
|
Clinical features |
Sudden fever, joint pain, and rash |
|
|
The febrile phase is relatively short, while migratory arthralgia is more pronounced and persistent. Severe pain elicited by pressure on the wrist joint is a key feature of this condition, and hemorrhage may occur in very rare cases. |
The febrile phase is prolonged, with widespread muscle, bone, and joint pain; congestive rashes or petechial hemorrhagic eruptions may be observed on the face and extremities, and some patients may exhibit bleeding manifestations of varying severity. |
|
|
Laboratory tests |
Antibody testing, nucleic acid testing, and virus isolation |
Antibody testing, antigen testing, nucleic acid testing, and virus isolation |
|
Treatment |
There is no specific medication for treatment; management is primarily symptomatic. |
There is no specific antiviral therapy; treatment is primarily symptomatic, and care should be taken to prevent bleeding. |
*Technical Guidelines for the Prevention and Control of Chikungunya Fever (2025 Edition)*
*Diagnostic and Treatment Protocol for Chikungunya Fever*
* Dengue Fever Prevention and Control Plan (2025 Edition)
*“Dengue Fever Diagnosis and Treatment Protocol (2024 Edition)”*
Dengue fever laboratory tests
During treatment, dengue fever patients… Aspirin, ibuprofen, and other nonsteroidal anti-inflammatory drugs should be used with caution to avoid exacerbating bleeding. Meanwhile, prevention and control efforts must be tailored to the specific pathogens involved. Multi-channel surveillance, along with case reporting and public health emergency reporting. Therefore, Accurate diagnosis of different pathogens It is of paramount importance to prevention and control efforts.
Previous articles have provided a detailed overview of laboratory testing for chikungunya fever. Accurate Diagnosis of Chikungunya Fever: Key Laboratory Testing Considerations and the JinHao Diagnostic Protocol Today, we will once again compare and introduce the laboratory tests for dengue fever.
The commonly used laboratory tests for dengue fever are likewise divided into these two categories:
Serological examination: antibody testing
Pathogenological examination: nucleic acid testing, virus isolation and identification, antigen detection
Because virus isolation and identification place high demands on laboratory facilities, involve complex procedures, and are prone to contamination, they are difficult for most laboratories to meet; therefore, this paper will not address them at this time.
Antibody testing
Antibody testing is divided into Serum-specific IgM antibodies and Serum-specific IgG antibodies 。
Serum-specific IgM antibodies Indicates a recent or acute infection; these are the earliest antibodies produced by the body following pathogen exposure. Type. In patients with primary infection, after the onset of illness… 3-5 IgM antibodies can be detected in the blood, reaching peak levels two weeks after disease onset.
Serum-specific IgG antibodies Indicates prior infection, chronic infection, the recovery phase, or immune protection. , appear later than IgM antibodies after infection. Onset One week later IgG antibodies can be detected; onset of illness. Within 1 week Detection of high-titer IgG antibodies suggests Secondary infection 。
Common methods for antibody detection include enzyme-linked immunosorbent assay (ELISA), colloidal gold immunoassay, and immunofluorescence antibody assay (IFA). Among these, the colloidal gold method is particularly well-suited for rapid screening due to its short assay time.
A positive serum-specific IgM antibody indicates a recent dengue virus infection. , suitable for the early diagnosis of dengue fever ; A fourfold or greater increase in the titer of dengue virus IgG antibodies from the acute phase to the convalescent phase, or seroconversion. It can serve as a basis for the definitive diagnosis of dengue fever.
Nucleic acid testing
Nucleic acid testing is a technique that directly detects the genetic material (DNA or RNA) of pathogens and is not exclusive to COVID‑19 testing. It is a cornerstone of modern infectious disease diagnosis. “Gold standard” One of them.
Dengue virus RNA was detected in patient specimens. It can serve as a basis for the definitive diagnosis of dengue fever.
Nucleic acid testing is also available. Viral Typing , confirm the dengue virus serotype infecting the patient.
In addition, nucleic acid testing can be performed on Aedes mosquito samples to characterize the genetic diversity and transmission dynamics of dengue virus, as well as the vectorial competence and viral load in these mosquitoes.
Antigen test
The NS1 antigen test is commonly used, typically after the onset of illness. Within 5 days The NS1 antigen detection rate in blood samples is high, making it suitable for rapid point-of-care testing.
Common methods for antigen detection include enzyme-linked immunosorbent assay (ELISA) and colloidal gold immunoassays. Among these, the colloidal gold method is better suited to rapid screening due to its short assay time.
Serum dengue virus antigen positive It can serve as a basis for the early diagnosis of dengue fever.
Jinhao Pharmaceutical Possessing independently developed and manufactured products of the
Chikungunya Virus Nucleic Acid Detection Kit (Fluorescent PCR Method)
Chikungunya Virus IgM/IgG Antibody Test Kit (Colloidal Gold Method)
Chikungunya Virus Antigen Detection Reagent (Colloidal Gold Method)
Dengue Virus Nucleic Acid Detection Kit (Fluorescent PCR Method) and Typing assay kit
Dengue IgM/IgG Antibody Test Kit (Colloidal Gold Method)
Dengue Virus Antigen Detection Reagent (Colloidal Gold Method)
and more diagnostic kits for vector-borne pathogens.
At the same time, it also has Zika Virus/Dengue Virus/Chikungunya Virus Triplex Nucleic Acid PCR Detection Kit (Fluorescent PCR Method) Multi‑channel multiplex assay kits can simultaneously differentiate Chikungunya virus, Zika virus, and Dengue virus in a single tube.
Jinhao Pharmaceutical offers a comprehensive suite of solutions for vector-borne pathogens, enabling precise pathogen detection and supporting epidemic prevention and control efforts.
Through rapid and accurate laboratory testing, achieve “ “Early detection, early reporting, early isolation, and early response” , effectively reducing the risk of epidemic spread.
Follow us
Phone: 400-650-6787 | 010-67878866 | Address: Building 1, No. 7 Yuncheng Street, Beijing Economic-Technological Development Area, Beijing |
© 2026 Beijing Jinhao Pharmaceutical Co., Ltd. All rights reserved | Beijing ICP Filing No. 17020135-2